Results 1 to 10 of about 4,432 (113)

SYNTHETIC SUBSTITUTES FOR QUINIDINE [PDF]

British Journal of Pharmacology and Chemotherapy, 1946
G. S. Dawes
openalex   +9 more sources

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Discussion on the Action of Quinidine in Cases of Cardiac Disease [PDF]

, 1923
A. E. Clark-Kennedy
  +7 more sources

LPS‐Induced Mitochondrial Damage via SLC41A1‐Mediated Magnesium Ion Efflux Leads to the Pyroptosis of Dental Stem Cells

Advanced Science, EarlyView.
Lipopolysaccharide induces upregulation of the magnesium (Mg2+) efflux transporter solute carrier family 41 member 1 in dental stem cells, leading to a decrease in intracellular Mg2+ concentration and promoting the binding of oligomycin sensitivity‐conferring protein and cyclophilinD.
Yuan Liu, Chenyu Song, Liyuan Zhang, Xue Han, Chaoyuan Li, Yanhong Yan, Ludan Xing, Mengting Si, Bo Yang, Lingyuan Cheng, Akimi Muramatsu, Beizhan Jiang   +11 more
wiley   +1 more source

Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open‐Label Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Imlunestrant (LY3484356) is a next‐generation orally bioavailable selective estrogen receptor degrader being investigated for the treatment of estrogen receptor–positive advanced breast and endometrial cancers. This Phase 1, open‐label, 2‐part study evaluated the disposition and absolute bioavailability of [14C]‐imlunestrant in 16 US‐based ...
Amita Datta‐Mannan, Boris Czeskis, Elaine Shanks, Eunice Yuen, Stephen Hall, Vivian Rodriguez Cruz, Kenneth Cassidy   +6 more
wiley   +1 more source

Exposure–Response Analysis for Aripiprazole Once‐Monthly in Patients Diagnosed With Bipolar I Disorder

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Aripiprazole once‐monthly (AOM) is approved for the maintenance monotherapy treatment of bipolar I disorder (BP‐I) in adults. A previously developed population pharmacokinetic model was validated by applying it to data from patients diagnosed with BP‐I.
Xiaofeng Wang, Luann Phillips, Matthew Harlin, Karimah S. Bell Lynum, Frank Larsen, Pedro Such, Jessica Madera‐McDonough, Murat Yildirim, Ric M. Procyshyn, Craig Chepke, Julie Passarell   +10 more
wiley   +1 more source

Predicting OCT2/MATEs‐Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium)

Clinical Pharmacology &Therapeutics, EarlyView.
Organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) transporters play significant roles in the renal secretion of organic cations and drug–drug interactions (DDIs). Recent in vitro studies indicate that the Ki values for OCT2 exhibit substrate dependency and increase in potency with pre‐incubation.
Satoshi Asano, Aleksandra Galetin, Yoshiko Tomita, Kathleen M. Giacomini, Xiaoyan Chu, Xinning Yang, Toshimichi Nakamura, Hiroyuki Kusuhara, Yuichi Sugiyama   +8 more
wiley   +1 more source

Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2D6 alleles with low frequency in Eurocentrically biased study populations are often excluded from pharmacogenetic investigation and consequently may have misassigned activity values. This health inequity may be contributing to imprecise dose predictions for CYP2D6‐metabolizing drugs.
Oyinlade Kehinde, Samuel E. Vaughn, Ogochukwu Amaeze, Paul Toren, Brandon Retke, Akinyemi Oni‐Orisan, Laura B. Ramsey   +6 more
wiley   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source